Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sera PrognosticsSERA -5.96%69 EV-to-EBIT is -1.10 as of Jul. 27, 2026. GuruFocus rates SERA with a GF Score™ of 69/100 and a GF Value™ of $1.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 214592.06% on this metric.
Sera Prognostics (NAS:SERA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sera Prognostics's Enterprise Value for the quarter that ended in Mar. 2026 was $34.57 Mil.
Sera Prognostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics EV-to-EBIT Related Terms
Sera Prognostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sera Prognostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's EV-to-EBIT falls into.
Sera Prognostics's current Enterprise Value is $35.38 Mil.
Sera Prognostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a EV-to-EBIT of -1.10 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Sera Prognostics' EV-to-EBIT too high?
Sera Prognostics' current EV-to-EBIT is -1.10. Based on the distribution chart, Sera Prognostics ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sera Prognostics has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' EV-to-EBIT compare to ZOMDF and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #999999 out of 466 companies for EV-to-EBIT. This places Sera Prognostics in the lower half of its industry. The industry median EV-to-EBIT is 18.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sera Prognostics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current EV-to-EBIT is -1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $2.05 — trading 12% above its estimated fair value. The current EV-to-EBIT is -1.10. Sera Prognostics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sera Prognostics (SERA), the current EV-to-EBIT is -1.10 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued.
The current stock price of $2.05 is trading 12% above its estimated GF Value™ of $1.83.
GuruFocus considers Sera Prognostics to be Modestly Overvalued.
Key valuation signals for SERA:
EV-to-EBIT: -1.10
GF Value™: $1.83 vs. price of $2.05 (12% above fair value)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
69GF Score
Get the complete analysis for SERA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
